Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis
2002; Lippincott Williams & Wilkins; Volume: 35; Issue: 2 Linguagem: Inglês
10.1053/jhep.2002.31607
ISSN1527-3350
Autores Tópico(s)Pediatric Hepatobiliary Diseases and Treatments
ResumoHepatologyVolume 35, Issue 2 p. 258-262 Perspectives In Clinical HepatologyFree Access Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis E. Anthony Jones, Corresponding Author E. Anthony Jones [email protected] Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The NetherlandsDepartment of Gastrointestinal and Liver Diseases, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam-ZO, The Netherlands. fax: (31) 20 691 7033.===Search for more papers by this author E. Anthony Jones, Corresponding Author E. Anthony Jones [email protected] Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The NetherlandsDepartment of Gastrointestinal and Liver Diseases, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam-ZO, The Netherlands. fax: (31) 20 691 7033.===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.31607Citations: 13AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, Gershwin ME, Coppel RL. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 2000; 174: 226– 237. MEDLINE 2 Medina J, Jones EA, Garcia-Monzon C, Moreno-Otero R. Immuno-pathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest 2001; 31: 64– 71. MEDLINE 3 Van de Water J, Ishibashi H, Coppel RL, Gershwin ME. Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology 2001; 33: 771– 775. MEDLINE 4 Metcalf J, Mitchison H, Palmer J, Jones DE, Bassendine MF, James OFW. Natural history of primary biliary cirrhosis. Lancet 1996; 458: 1399– 1402. 5 Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 1990; 98: 1567– 1571. MEDLINE 6 Lim AG, Jazrawi RP, Northfield TC. The ursodeoxycholic acid story in primary biliary cirrhosis. Gut 1995; 37: 301– 304. MEDLINE 7 Combes B. Ursodeoxycholic acid in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 125– 128. MEDLINE 8 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12– 15. MEDLINE 9 Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroent Hepatol 1998; 13: 659– 664. 10 Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104: 1865– 1870. MEDLINE 11 Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 1992; 102: 1389– 1391. MEDLINE 12 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053– 1060. MEDLINE 13 Kaplan MM. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Semin Liver Dis 1997; 17: 129– 136. MEDLINE 14 Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid. J Hepatol 1993; 18: 9– 14. MEDLINE 15 Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Weisner RH, Gores GJ, Lange SM, et al. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis: the results of a pilot study. Hepatology 1995; 22: 1158– 1162. MEDLINE 16 Bergasa NV, Jones EA, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH. Pilot study of low dose methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol 1996; 91: 295– 299. MEDLINE 17 Conjeevaram HS, Bergasa NV, Kleiner DE, Sallie R, Wells M, Hoofnagle JH. Methotrexate therapy of primary biliary cirrhosis: 2 yr study comparing two doses [Abstract]. Hepatology 1995; 22: 124A. 18 Vandeputter L, van Steenbergen W. Methotrexate therapy in primary biliary cirrhosis is of limited efficacy and accompanied by serious side effects [Abstract]. Gastroenterology 1997; 112: A1406. 19 Hendrickse M, Rigney E, Giaffer MH, Soomoro I, Triger DR, Underwood JC, Gleeson D. Low-dose methotrexate in primary biliary cirrhosis. Long-term results of a placebo-controlled trial [Abstract]. Hepatology 1997; 26: 248A. 20 Bach N, Bodian C, Thung S, Croen E, Bodenheimer H Jr, Schaffner F. Methotrexate therapy for primary biliary cirrhosis: five year follow up [Abstract]. Hepatology 1998; 28: 545A. 21 Munoz S, Carithers RL Jr, Emerson SS, Flye N, Kowdley K, Combes B. Absence of pulmonary toxicity in primary biliary cirrhosis (PBC) treated with methotrexate and ursodiol [Abstract]. Hepatology 1998; 28: 392A. 22 Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OFW. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10: 420– 429. MEDLINE 23 Howat HT, Ralston AJ, Varley H, Wilson JA. The late results of long-term treatment of primary biliary cirrhosis by corticosteroids. Rev Internat Hepatol 1966; 16: 227– 238. 24 Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5– 28. MEDLINE 25 Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85– 118. MEDLINE 26 Allison AC, Hovi T, Watts RWE, Webster ADB. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975; 2: 1179. MEDLINE 27 Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067. MEDLINE 28 Griesmacher A, Weigel G, Seebacher G, Muller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997; 43: 2312– 2317. MEDLINE 29 Mitsui A, Suzuki S. Immunosuppressive effect of mycophenolic acid. J Antibiot (Tokyo) 1969; 22: 358– 363. MEDLINE 30 Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res 1976; 36: 2923– 2927. MEDLINE 31 Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Amer Acad Derm 1979; 1: 531– 537. 32 Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. J Amer Acad Derm 1987; 17: 962– 971. 33 Bullingham R, Monroe S, Nichols A, Hale M. Pharmacokinetics of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharm 1996; 36: 315– 324. 34 Bullingham RE, Nichols A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996; 28: 925– 929. MEDLINE 35 Bullingham RES, Nichols AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429– 455. MEDLINE 36 Sollinger HW. From mice to man: the preclinical history of mycophenolate mofetil. Clin Transplant 1996; 10: 85– 92. MEDLINE 37 Gray DW. Mycophenolate mofetil for transplantation: new drug, old problems? Lancet 1995; 346: 390. MEDLINE 38 Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11(Suppl 8): S117– S119. MEDLINE 39 Radford-Smith GL, Taylor P, Florin THJ. Mycophenolate mofetil in IBD patients. Lancet 1999; 354: 1386– 1387. MEDLINE 40 Finzi D, Siliciano RF. Taking aim at HIV replication. Nat Med 2000; 6: 735– 736. MEDLINE 41 Chapuis AG, Rizzardi P, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6: 762– 768. MEDLINE 42 Alfieri C, Allison AC, Kieff E. Effect of mycophenolic acid on Epstein-Barr virus infection of human lymphocytes. Antimicrob Agents Chemother 1994; 38: 126. MEDLINE 43 Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Amer J Health-System Pharm 1997; 54: 285– 294. 44 Silverman Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Amer Acad Dermatol 1997; 37: 445– 449. 45 Dissanayake IR, Goodman GR, Bowman AR, Ma Y, Pun S, Jee WS, Epstein S. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275– 278. MEDLINE 46 Jones EA, Bergasa NV. Immunosuppressive treatment of chronic liver disease. In: AC Allison, KJ Lafferty, H Fliri, eds. Immunosuppressive and Antiinflammatory Drugs. Ann N Y Acad Sci 1993; 696: 319– 327. MEDLINE 47 Jones EA, ten Kate FJW, ter Borg F, Houben M, Reesink HW, Chamuleau RAFM. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastrenterol Hepatol 1999; 11: 1165– 1169. 48 Jones EA, ten Kate FJW, Hoek FJ, Chamuleau RAFM. Mycophenolate mofetil: a potential long-term immunosuppressant treatment for primary biliary cirrhosis. In: R Moreno-Otero, G Clemente-Rocote, C Garcia-Monzon, eds. Immunology and the Liver: Autoimmunity. Madrid: Aran Ediciones, 2000: 203– 207. 49 Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determinations of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model. Hepatology 1991; 14: 504– 510. MEDLINE 50 Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharm 1996; 36: 332– 344. 51 Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22– 27. MEDLINE Citing Literature Volume35, Issue2February 2002Pages 258-262 ReferencesRelatedInformation
Referência(s)